Skip to main content


The advent of immunotherapy has resulted in significant survival benefits in cancer care. The immune response is however heterogeneous across tumors and individuals, rendering existing therapeutics non-effective for many patients. My research focuses on identification of biomarker signatures for patient stratification and new treatment strategies through comprehensive characterization of the tumor immune microenvironment.  

Spatial omics

Infiltration and tumor proximity of distinct immune phenotypes have been correlated to cancer initiation, progression and resistance, indicating the vast potential for patient tailored strategies based on spatial measurement of multiple phenotypes and tumor/immune checkpoint markers. We are now able to generate detailed depictions of tumor immune microenvironments through spatially guided, highly multiplex proteomic and transcriptomic profiling of tumor biopsies down to single-cell resolution. In combination with orthogonal transcriptomic and genomic methods, we apply spatial omics to generate prediction models and thereby identify companion biomarkers for individualized treatment selection and candidate targets for immuno-oncology.



  1. Ovarian cancer
  2. Lung cancer
Anna Sandström Gerdtsson. Portrait.

Anna Sandström Gerdtsson

Department of Immunotechnology
Lund University
Medicon Village; Bldg 406
223 81 Lund, Sweden

Page Manager: | 2021-08-19